AMEX · Biotechnology

IGC (IGC) Stock

$0.26 +2.68% AMEX: IGC Healthcare

Valuation

MetricValue
Price$0.26
Market Cap$25.68M
P/E Ratio—
P/B Ratio4.63
P/S Ratio23.41
EPS (TTM)$-0.09
52-Week High$0.50
52-Week Low$0.24
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE—
ROA—
ROCE—
Gross Margin29.68%
Operating Margin-8.60%
Net Margin-5.52%
Debt/Equity0.00
Current Ratio0.33

Annual Financials (USD)

Metric20222023202420252026
Revenue$0$1.0M$1.0M$1.0M—
Operating Profit$-15.0M$-12.0M$-10.0M$-7.0M—
Net Profit$-15.0M$-12.0M$-13.0M$-7.0M—
EPS$-0.30$-0.22$-0.22$-0.09—
Op Margin-3886.2%-1270.1%-728.5%-585.8%—

Balance Sheet (USD)

Metric20222023202420252026
Total Assets$27.0M$17.0M$10.0M$9.0M$9.0M
Total Liabilities$3.0M$2.0M$3.0M$2.0M$3.0M
Cash$10.0M$3.0M$1.0M$0$0
Borrowings$1.0M$0$0$0$0

Latest News

IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow ACCESS Newswire · Jul 9, 2026 IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company ACCESS Newswire · Jul 7, 2026 IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow ACCESS Newswire · Jun 23, 2026 IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis ACCESS Newswire · Jun 11, 2026 Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts ACCESS Newswire · Jun 9, 2026

Cash Flow (USD)

Metric20222023202420252026
Operating Cash Flow$-7.0M$-7.0M$-5.0M$-5.0M—
Investing Cash Flow$-2.0M$-1.0M$-1.0M$-1.0M—
Financing Cash Flow$0$0$0$0—
Net Cash Flow$-4.0M$-7.0M$-2.0M$-1.0M—
Free Cash Flow$-8.0M$-8.0M$-6.0M$-5.0M$0

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-22.00%
Quick Ratio0.18
Interest Coverage—
Return 1Y-21.62%
Return 3Y-27.97%
Return 5Y-81.10%

Ownership

Insiders Held13.38%
Institutions Held21.71%
Institutions Float Held25.06%
Institutional HolderSharesReport Date
Geode Capital Management, LLC1,043,3842026-03-31
Vanguard Capital Management LLC718,4362026-03-31
Blackrock Inc.703,7982026-03-31
Renaissance Technologies, LLC483,9752026-03-31
Vanguard Fiduciary Trust Co415,8882026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANTX $4.93 +0.20% -4.76 $177.56M 0.00%
BOLD $2.48 -3.50% -0.56 $55.74M 0.00%
INTS $4.57 +2.70% -0.60 $12.35M 0.00%
ITRMIterum Therapeutics plc $0.03 -10.98% -0.06 $1.60M 0.00%
NTRB $3.11 +6.69% -1.40 $37.81M 0.00%

About IGC

IGC is led by CEO Ram Mukunda, employs 67 people, headquartered in US, publicly traded since 2006.

IGC stock trades at $0.26 with a market capitalization of $25.68M. The stock is valued at price-to-book of 4.63, price-to-sales of 23.41. Over the past 52 weeks the stock has ranged between $0.24 and $0.50, and currently trades 48.0% below its 52-week high.

On profitability, IGC generates an operating margin of -8.60%, a net profit margin of -5.52%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides